The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Oncology Drug Shortages Persist, but Continue to Evolve

2.

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

3.

Relationship-building key to addressing oncologist shortages in rural care

4.

Daily physical activity, even at light intensities, linked to lower cancer risk

5.

Waiting for a Sharp Increase in Prostate Cancer Cases.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot